23 Paroxetine Images and Stock Photos

View paroxetine videos

Browse 20+ paroxetine stock photos and images available, or start a new search to explore more stock photos and images.

Our creative library is free of AI-generated contentChoose your visuals with confidence knowing our creative library is free from AI-generated content, so your searches only return safe, high-quality visuals you can trust.
Agomelatine Merida, Mexico - May 25, 2013: Agomelatine is a novel melatonergic antidepressant developed by the pharmaceutical company Servier and currently not available in the US.In March 2006, Servier announced it had sold the rights to market agomelatine in the United States to Novartis. It was undergoing several phase III clinical trials in the US, and until October 2011 Novartis listed the drug as scheduled for submission to the FDA no earlier than 2012. However, the development for the US market was discontinued in October 2011, when the results from the last of those trials became available. paroxetine stock pictures, royalty-free photos & images
Agomelatine Merida, Mexico - May 25, 2013: Agomelatine is a novel melatonergic antidepressant developed by the pharmaceutical company Servier and currently not available in the US.In March 2006, Servier announced it had sold the rights to market agomelatine in the United States to Novartis. It was undergoing several phase III clinical trials in the US, and until October 2011 Novartis listed the drug as scheduled for submission to the FDA no earlier than 2012. However, the development for the US market was discontinued in October 2011, when the results from the last of those trials became available. paroxetine stock pictures, royalty-free photos & images

Merida, Mexico - May 25, 2013: Agomelatine is a novel melatonergic antidepressant developed by the pharmaceutical company Servier and currently not available in the US.In March 2006, Servier announced it had sold the rights to market agomelatine in the United States to Novartis. It was undergoing several phase III clinical trials in the US, and until October 2011 Novartis listed the drug as scheduled for submission to the FDA no earlier than 2012. However, the development for the US market was discontinued in October 2011, when the results from the last of those trials became available.

Take any image from "not quite" to "just right"See how you can modify existing images — or generate entirely new ones — to your exact needs.
Discover Unlimited AI